-
1
-
-
0032855594
-
Prostate specific antigen: A decade of discovery - What we have learned and where we are going
-
Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999 162 : 293 306
-
(1999)
J Urol
, vol.162
, pp. 293-306
-
-
Polascik, T.J.1
Oesterling, J.E.2
Partin, A.W.3
-
2
-
-
0026077430
-
Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin
-
Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 1991 37 : 1618 25
-
(1991)
Clin Chem
, vol.37
, pp. 1618-25
-
-
Lilja, H.1
Christensson, A.2
Dahlen, U.3
-
3
-
-
0026027671
-
A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
-
Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991 51 : 222 6
-
(1991)
Cancer Res
, vol.51
, pp. 222-6
-
-
Stenman, U.H.1
Leinonen, J.2
Alfthan, H.3
Rannikko, S.4
Tuhkanen, K.5
Alfthan, O.6
-
4
-
-
0033813076
-
The clinical impact of different assays for prostate specific antigen
-
Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000 86 : 590 7
-
(2000)
BJU Int
, vol.86
, pp. 590-7
-
-
Semjonow, A.1
De Angelis, G.2
Oberpenning, F.3
Schmid, H.P.4
Brandt, B.5
Hertle, L.6
-
5
-
-
0035729131
-
Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer
-
Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001 88 : 545 50
-
(2001)
BJU Int
, vol.88
, pp. 545-50
-
-
Blijenberg, B.G.1
Yurdakul, G.2
Van Zelst, B.D.3
Bangma, C.H.4
Wildhagen, M.F.5
Schroder, F.H.6
-
6
-
-
0030473107
-
Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen
-
Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 1996 48 (Suppl. 10 5
-
(1996)
Urology
, vol.48
, Issue.SUPPL.
, pp. 10-5
-
-
Semjonow, A.1
Oberpenning, F.2
Brandt, B.3
Zechel, C.4
Brandau, W.5
Hertle, L.6
-
7
-
-
0032146613
-
Reference material for PSA: The IFCC standardization study. International Federation of Clinical Chemistry
-
Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry. Clin Biochem 1998 31 : 475 81
-
(1998)
Clin Biochem
, vol.31
, pp. 475-81
-
-
Stamey, T.A.1
Chen, Z.2
Prestigiacomo, A.F.3
-
8
-
-
0033816633
-
Reference reagents for prostate-specific antigen (PSA): Establishment of the first international standards for free PSA and PSA (90: 10)
-
Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90: 10). Clin Chem 2000 46 : 1310 7
-
(2000)
Clin Chem
, vol.46
, pp. 1310-7
-
-
Rafferty, B.1
Rigsby, P.2
Rose, M.3
Stamey, T.4
Gaines Das, R.5
-
9
-
-
0034921199
-
Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer?
-
Semjonow A, Oberpenning F, Weining C et al. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem 2001 47 : 1472 5
-
(2001)
Clin Chem
, vol.47
, pp. 1472-5
-
-
Semjonow, A.1
Oberpenning, F.2
Weining, C.3
-
10
-
-
0030339750
-
Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values
-
Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 1996 7 : 3 16
-
(1996)
Prostate Suppl
, vol.7
, pp. 3-16
-
-
Semjonow, A.1
Brandt, B.2
Oberpenning, F.3
Roth, S.4
Hertle, L.5
-
11
-
-
2442526439
-
Variation in prostate specific antigen results from 2 different assay platforms: Clinical impact on 2304 patients undergoing prostate cancer screening
-
Link RE, Shariat SF, Nguyen CV et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004 171 : 2234 8
-
(2004)
J Urol
, vol.171
, pp. 2234-8
-
-
Link, R.E.1
Shariat, S.F.2
Nguyen, C.V.3
-
12
-
-
0034125518
-
A comparison of six commercial assays for total and free prostate specific antigen (PSA): The predictive value of the ratio of free to total PSA
-
Patel D, White PA, Milford WA. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 2000 85 : 686 9
-
(2000)
BJU Int
, vol.85
, pp. 686-9
-
-
Patel, D.1
White, P.A.2
Milford, W.A.3
-
13
-
-
33746633333
-
Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation
-
Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006 52 : 1568 74
-
(2006)
Clin Chem
, vol.52
, pp. 1568-74
-
-
Kort, S.A.1
Martens, F.2
Vanpoucke, H.3
Van Duijnhoven, H.L.4
Blankenstein, M.A.5
-
14
-
-
30844455114
-
Prostate-specific antigen: Bias and molarity of commercial assays for PSA in use in England
-
NHS Prostate Cancer Risk Management Programme.
-
Roddam AW, Rimmer J, Nickerson C, Ward AM NHS Prostate Cancer Risk Management Programme. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006 43 : 35 48
-
(2006)
Ann Clin Biochem
, vol.43
, pp. 35-48
-
-
Roddam, A.W.1
Rimmer, J.2
Nickerson, C.3
Ward, A.M.4
-
15
-
-
29744462375
-
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: An update
-
Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006 52 : 59 64
-
(2006)
Clin Chem
, vol.52
, pp. 59-64
-
-
Stephan, C.1
Klaas, M.2
Muller, C.3
Schnorr, D.4
Loening, S.A.5
Jung, K.6
-
16
-
-
0029008314
-
Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows
-
Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest Suppl 1995 222 : 43 60
-
(1995)
Scand J Clin Lab Invest Suppl
, vol.222
, pp. 43-60
-
-
Kairisto, V.1
Poola, A.2
-
17
-
-
0029951253
-
Analytical performance and clinical validity of two free prostate-specific antigen assays compared
-
Jung K, Stephan C, Lein M et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996 42 : 1026 33
-
(1996)
Clin Chem
, vol.42
, pp. 1026-33
-
-
Jung, K.1
Stephan, C.2
Lein, M.3
-
18
-
-
0343593693
-
Prostate cancer detection at low prostate specific antigen
-
Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000 163 : 806 12
-
(2000)
J Urol
, vol.163
, pp. 806-12
-
-
Schröder, F.H.1
Van Der Cruijsen-Koeter, I.2
De Koning, H.J.3
Vis, A.N.4
Hoedemaker, R.F.5
Kranse, R.6
-
19
-
-
0032770605
-
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51-4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model
-
Catalona WJ, Partin AW, Finlay JA et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51-4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999 54 : 220 4
-
(1999)
Urology
, vol.54
, pp. 220-4
-
-
Catalona, W.J.1
Partin, A.W.2
Finlay, J.A.3
-
20
-
-
2442715038
-
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
-
Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 46
-
(2004)
N Engl J Med
, vol.350
, pp. 2239-46
-
-
Thompson, I.M.1
Pauler, D.K.2
Goodman, P.J.3
-
21
-
-
0028256194
-
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men
-
Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994 151 : 1283 90
-
(1994)
J Urol
, vol.151
, pp. 1283-90
-
-
Catalona, W.J.1
Richie, J.P.2
Ahmann, F.R.3
-
22
-
-
33749512355
-
Ann Clin Biochem 2006; 43: 35-48
-
Accuracy assessment of PSA methods must be based on clinical instead of artificial samples - a response to AW Roddam*et al.
-
Stephan C, Semjonow A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples - a response to AW Roddam et al. Ann Clin Biochem 2006; 43: 35-48. Ann Clin Biochem 2006 43 : 421 2
-
(2006)
Ann Clin Biochem
, vol.43
, pp. 421-2
-
-
Stephan, C.1
Semjonow, A.2
-
23
-
-
0032550630
-
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
-
Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 279 : 1542 7
-
(1998)
JAMA
, vol.279
, pp. 1542-7
-
-
Catalona, W.J.1
Partin, A.W.2
Slawin, K.M.3
|